Janus Henderson Group
ALGS icon

Janus Henderson Group’s Aligos Therapeutics ALGS Stock Holding History

Janus Henderson Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68,817
Closed -$3.7M – 2595
2022
Q1 		$3.7M Sell
68,817
-27,968
-29% -$2.24M ﹤0.01% 1076
2021
Q4 		$28.7M Sell
96,785
-834
-0.9% -$304K 0.01% 700
2021
Q3 		$37.7M Buy
97,619
+7,228
+8% +$2.86M 0.02% 630
2021
Q2 		$45.8M Buy
90,391
+1,189
+1% +$758K 0.02% 591
2021
Q1 		$48.7M Buy
89,202
+13,443
+18% +$8.95M 0.02% 557
2020
Q4 		$50M Buy
+75,759
New +$36.9M 0.02% 536

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group's ALGS Position: Q2 2022 in Review

Janus Henderson Group sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 68,817 shares — an estimated $3.7M sold.

Janus Henderson Group first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $50M in Q4 2020. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Janus Henderson Group reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Janus Henderson Group sold 68,817 Aligos Therapeutics shares in Q2 2022, an estimated $3.7M.
  • Janus Henderson Group first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
  • Janus Henderson Group's Aligos Therapeutics position peaked at $50M in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.